Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news

Dexamethasone Harmful in Chronic Subdural Hematoma Dexamethasone Harmful in Chronic Subdural Hematoma
The steroid, which is commonly used as a treatment for chronic subdural hematoma, appears to be doing more harm than good in this indication, a new randomized trial has shown.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 7, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Dexamethasone Not Favored for Chronic Subdural Hematoma
Dexamethasone worse than placebo with respect to favorable outcome at six months (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 30, 2020 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Dexamethasone Not Favored for Chronic Subdural Hematoma
WEDNESDAY, Dec. 30, 2020 -- Dexamethasone results in fewer favorable outcomes than placebo among patients with symptomatic chronic subdural hematoma, according to a study published online Dec. 16 in the New England Journal of Medicine. Peter J.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 30, 2020 Category: Pharmaceuticals Source Type: news

The breakthrough medicines that could change the course of Covid
Dexamethasone demonstrates power of large-scale, randomised trials in finding effective medicinesCoronavirus – latest updatesSee all our coronavirus coverageIt remains one of the most dramatically successful outcomes in the battle against Covid-19. A cheap treatment for inflammation was found to save lives of seriously ill patients while a trio of much-touted therapies were shown to have no effect.It is now estimated that the discovery of the effectiveness of the drug dexamethasone has saved around 650,000 lives across the world, according to Professor Martin Landray, a founder of the Recovery programme – the w...
Source: Guardian Unlimited Science - December 27, 2020 Category: Science Authors: Robin McKie Observer Science Editor Tags: Coronavirus Medical research Biology UK news Infectious diseases Health World news Science Society Source Type: news

Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma Dexamethasone May Nix Immunotherapy Benefit in Glioblastoma
Investigators found that baseline dexamethasone use was associated with poor overall survival (OS) in glioblastoma patients receiving anti –PD-1 or anti–PD-L1 therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What Bill Gates Thinks About the State of the Fight Against COVID-19
Bill Gates isn’t about to be contemplating his touchdown dance yet. You don’t get to devote your life to battling the world’s most intractable problems by declaring victory before a fight is over. But in a letter Gates released this morning, headlined, “These breakthroughs will make 2021 better than 2020,” it’s clear that the co-director of the Bill and Melinda Gates Foundation is feeling pretty sanguine about the year ahead—particularly when it comes to COVID-19. The Gates letter, which comes a month before the expected January release of Melinda Gates’s Annual Letter, sees ...
Source: TIME: Health - December 22, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

Covid Guide: How to Get Through the Pandemic
Times are tough now, but the end is in sight. If we hunker down, keep our families safe during the holidays and monitor our health at home, life will get better in the spring. Here ’s how to get through it. (Source: NYT Health)
Source: NYT Health - December 19, 2020 Category: Consumer Health News Authors: Tara Parker-Pope Tags: Coronavirus Risks and Safety Concerns Disease Rates Chronic Condition (Health) Coronavirus (2019-nCoV) Dexamethasone (Drug) Telemedicine Vaccination and Immunization Travel Warnings Tests (Medical) Protective Clothing and Gear Winter ( Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Dexamethasone Therapy Poses High Risk for Patients With Chronic Subdural Hematoma Dexamethasone Therapy Poses High Risk for Patients With Chronic Subdural Hematoma
Treating chronic subdural hematoma with dexamethasone may do more harm than good, producing less favorable outcomes and more side effects than placebo, according to a new U.K. study that randomized 748 patients.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 17, 2020 Category: Surgery Tags: Internal Medicine News Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Special Topics - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Operations - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS: Journal of Emergency Medical Services News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Latest News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Administration and Leadership - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Patient Care - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Extraction with an electric motor-driven handpiece may still cause subcutaneous emphysema - A case report
This article reported a case of SE around the paraorbital and submandibular regions through extractions of teeth 28 and 38. This 20-year-old man came to the emergency room at night with the major complaint of pain and discomfort during swallowing. Sudden swelling at his left face during extractions of teeth 28 and 38 three hours ago was mentioned. The original surgeon who performed the odontectomy was aware of the SE after removing the surgical drape and specific post-operation instructions were given as follows: immediate hospital care may be needed if the patient encountered difficulties in swallowing or any worsen compl...
Source: Dental Technology Blog - December 14, 2020 Category: Dentistry Source Type: news

Covid Patient Study Shows Some Benefit From an Arthritis Drug
Baricitinib had previously attracted some scrutiny from experts, who were unsure when it would most help their patients. (Source: NYT Health)
Source: NYT Health - December 13, 2020 Category: Consumer Health News Authors: Katherine J. Wu Tags: Dexamethasone (Drug) Remdesivir (Drug) Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Clinical Trials Steroids New England Journal of Medicine your-feed-healthcare Source Type: news

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
The subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone showed significant improvement in progression-free survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
TUESDAY, Dec. 8, 2020 -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Baricitinib: Doctors Are Skeptical of This Covid-19 Drug From Eli Lilly
Baricitinib, an arthritis drug made by Eli Lilly, may reduce recovery time by a day, but costs about $1,500 and comes with side effects. (Source: NYT Health)
Source: NYT Health - December 4, 2020 Category: Consumer Health News Authors: Katherine J. Wu Tags: Dexamethasone (Drug) Medical Devices Drugs (Pharmaceuticals) Clinical Trials Research Steroids Source Type: news

Dexamethasone May Curb Efficacy of Immune Checkpoint Blockade in Glioblastoma Dexamethasone May Curb Efficacy of Immune Checkpoint Blockade in Glioblastoma
Dexamethasone given to combat cerebral edema in patients with glioblastoma may negatively affect immunotherapy, according to work in mice and clinical data.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Dexamethasone May Hinder Immunotherapy for Glioblastoma
THURSDAY, Dec. 3, 2020 -- For patients with glioblastoma (GBM) receiving immune checkpoint inhibitors, concurrent dexamethasone is associated with worse survival, according to a study published online Nov. 25 in Clinical Cancer Research. J. Bryan... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2020 Category: Pharmaceuticals Source Type: news

The effect of oral dexamethasone administration on testosterone levels in combat veterans with or without a history of suicide attempt - Sher L, Bierer LM, Makotkine I, Yehuda R.
In this study, we examined morning baseline free and total testosterone levels... (Source: SafetyLit)
Source: SafetyLit - December 1, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasone
(American Association for Cancer Research) Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 25, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 therapy: corticosteroids including dexamethasone and hydrocortisone
In accordance with World Health Organization (WHO) recommendations, systemic corticosteroids should be used in patients with severe and critical COVID-19 disease, but not in patients with non-severe C (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 20, 2020 Category: Drugs & Pharmacology Source Type: news

Triplet Therapy Slows Refractory Multiple Myeloma
WEDNESDAY, Nov. 18, 2020 -- A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. Sebastian Grosicki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 therapy: corticosteroids including dexamethasone and hydrocortisone, NHS England
In accordance with World Health Organization (WHO) recommendations, this letter explains that systemic corticosteroids should be used in patients with severe and critical COVID-19 disease, but not in patients with non-severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 17, 2020 Category: Consumer Health News Source Type: news

Cytokine storms play a limited role in moderate-to-severe COVID-19
Rather than life-threatening hyperinflammation, most adults with moderate-to-severe COVID-19 have a suppressed viral immune response when compared to adults with another viral respiratory infection, influenza. St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis led research that suggests most COVID-19 patients are not candidates for treatment with steroids such as dexamethasone. (Source: World Pharma News)
Source: World Pharma News - November 16, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Allows Emergency Use of Antibody Drug to Fight COVID-19
(WASHINGTON) — U.S. health officials have allowed emergency use of the first antibody drug to help the immune system fight COVID-19, an experimental approach against the virus that has killed more than 238,000 Americans. The Food and Drug Administration on Monday cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. It’s a one-time treatment given through an IV. The therapy is still undergoing additional testing to establish its safety and effectiveness. It is similar to a treatment President Donald Trump received after contracting the...
Source: TIME: Health - November 10, 2020 Category: Consumer Health News Authors: Matthew Perrone / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

New discovery may change how dexamethasone is prescribed for some COVID-19 patients
(DOE/Argonne National Laboratory) New insights into the way the body distributes dexamethasone could mean that patients with high blood sugar may see diminished effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2020 Category: International Medicine & Public Health Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. Sets New Daily COVID-19 Record Amid Election Turmoil
New confirmed cases of the coronavirus in the U.S. have climbed to an all-time high of more than 86,000 per day on average, in a glimpse of the worsening crisis that lies ahead for the winner of the presidential election. Cases and hospitalizations are setting records all around the country just as the holidays and winter approach, demonstrating the challenge that either President Donald Trump or former Vice President Joe Biden will face in the coming months. Daily new confirmed coronavirus cases in the U.S. have surged 45% over the past two weeks, to a record 7-day average of 86,352, according to data compiled by Johns Ho...
Source: TIME: Health - November 5, 2020 Category: Consumer Health News Authors: Lindsey Tanner / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

U.S. COVID-19 Cases Are Skyrocketing, But Deaths Are Flat —So Far. These 5 Charts Explain Why
In just the last two weeks, the global daily tally for new COVID-19 cases has jumped more than 30%, according to TIME’s coronavirus tracker, which compiles data from Johns Hopkins University. The steep upward trend is driven by viral waves in Europe and the United States that started in August and mid-September, respectively. On Oct. 23, the daily case count in the U.S. reached a new record high, suggesting that this wave will be worse than the one that swept the country over the summer. But despite this rapid uptick in cases, the daily death count in the U.S. is not yet rising at the same rate, and remains at lower ...
Source: TIME: Health - October 26, 2020 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news

COVID-19: Dexamethasone discovery carries treatment implications
(University of Virginia Health System) A new finding about dexamethasone suggests diabetes and other factors may reduce its potentially lifesaving effectiveness for patients with severe COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2020 Category: International Medicine & Public Health Source Type: news

Melania Trump used "vitamins and healthy food" to cure coronavirus
(Natural News) Instead of downing a pharmaceutical cocktail of remdesivir, the steroid dexamethasone, and an experimental antibody regimen made from Regeneron like her husband did, First Lady Melania Trump decided to take “a more natural route” in treating her Wuhan coronavirus (COVID-19) positive test result with vitamins and healthy food. Though she did not specify any... (Source: NaturalNews.com)
Source: NaturalNews.com - October 20, 2020 Category: Consumer Health News Source Type: news

Featured Review: Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis
ConclusionsFor people at higher risk, some medicines worked well to stop them from being sick after general anaesthesia. The most reliable antiemetic medicines were aprepitant, ramosetron, granisetron, dexamethasone, and ondansetron, followed by fosaprepitant and droperidol.However, the authors did not find enough reliable evidence about potential unwanted effects to rank these medicines reliably according to how well they worked.Read the full review on the Cochrane LibraryVisit the Cochrane Anaesthesia Group websiteTuesday, October 20, 2020 (Source: Cochrane News and Events)
Source: Cochrane News and Events - October 15, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news

Could Trump Spread Coronavirus at Town Hall? Likely Not, Experts Say
While questions have surrounded the timing and severity of the president ’s illness, health experts said he was unlikely to infect people at Thursday’s town hall event on NBC. (Source: NYT Health)
Source: NYT Health - October 15, 2020 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Trump, Donald J United States Politics and Government Presidential Election of 2020 White House Coronavirus Outbreak (2020) Coronavirus (2019-nCoV) NBC News Television Dexamethasone (Drug) your-feed-science Coronavirus Risks and Safety C Source Type: news

For How Long Will President Trump Be Immune to the Coronavirus?
A unique treatment course may have blunted his body ’s production of antibodies, scientists warn. (Source: NYT Health)
Source: NYT Health - October 14, 2020 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Antibodies White House Coronavirus Outbreak (2020) Dexamethasone (Drug) Coronavirus (2019-nCoV) Steroids Regeneron Pharmaceuticals Inc Biden, Joseph R Jr Trump, Donald J Presidential Election of 2020 Source Type: news

A Dose of Optimism, as the Pandemic Rages On
The months ahead will be difficult. But the medical cavalry is coming, and the rest of us know what we need to do. (Source: NYT Health)
Source: NYT Health - October 13, 2020 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Clinical Trials Dexamethasone (Drug) Disease Rates Coronavirus (2019-nCoV) Vaccination and Immunization Deaths (Fatalities) Drugs (Pharmaceuticals) Source Type: news

Dexamethasone for Macular Edema Unresponsive to Anti-VEGF Dexamethasone for Macular Edema Unresponsive to Anti-VEGF
For patients with diabetic macular edema, a quick and complete switch to dexamethasone after a failure to respond to anti-VEGF therapy could be effective, findings from two studies show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 9, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Letters to the Editor: Trump is on a steroid that can cause mania. We should be worried
A reader describes her son's behavior while on dexamethasone, including feelings of euphoria and overconfidence. (Source: L.A. Times - Health)
Source: L.A. Times - Health - October 9, 2020 Category: Consumer Health News Source Type: news

Trump Could Be Back in Public by Saturday. Experts Worry It ’s Too Soon.
The White House physician, Dr. Sean P. Conley, predicted that the president could safely return to “public engagements.” Experts questioned the doctor’s rationale. (Source: NYT Health)
Source: NYT Health - October 9, 2020 Category: Consumer Health News Authors: Katherine J. Wu Tags: White House Coronavirus Outbreak (2020) Coronavirus (2019-nCoV) Presidential Election of 2020 Dexamethasone (Drug) Steroids Centers for Disease Control and Prevention Regeneron Pharmaceuticals Inc Trump, Donald J Conley, Sean Patrick Source Type: news

Trump Was Treated With Steroids: How These Drugs Are Used For COVID-19 Patients
The drug dexamethasone is a cheap, widely available steroid. But how long should COVID-19 patients take it, and what are the side effects?(Image credit: Nati Harnik/AP) (Source: NPR Health and Science)
Source: NPR Health and Science - October 8, 2020 Category: Consumer Health News Authors: Rhitu Chatterjee Source Type: news